AChE-IN-23

CAS No. 6297-14-9

AChE-IN-23( —— )

Catalog No. M32706 CAS No. 6297-14-9

AChE-IN-23 (compound 3h) is an acetylcholinesterase (AChE) inhibitor with an IC50 value of 48.3 μM .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 37 In Stock
50MG 28 In Stock
100MG 43 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AChE-IN-23
  • Note
    Research use only, not for human use.
  • Brief Description
    AChE-IN-23 (compound 3h) is an acetylcholinesterase (AChE) inhibitor with an IC50 value of 48.3 μM .
  • Description
    AChE-IN-23 (compound 3h) is an acetylcholinesterase (AChE) inhibitor with an IC50 value of 48.3 μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    6297-14-9
  • Formula Weight
    267.194
  • Molecular Formula
    C11H20Cl2N2O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (374.25 mM; Ultrasonic)
  • SMILES
    Cl.Cl.CCN(CC)Cc1cc(N)ccc1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Martijn Constantijn de Koning, et al. Discovery of a potent non-oxime reactivator of nerve agent inhibited human acetylcholinesterase. Eur J Med Chem. 2018 Sep 5;157:151-160.?
molnova catalog
related products
  • Isoviolanthin

    Isoviolanthin reduces the migratory and invasive capacities of TGF-β1-treated HCC cells but exhibits no cytotoxic effects on normal live cells, and has potential as a therapeutic agent for the treatment of advanced-stage metastatic HCC.

  • Rubiadin

    Rubiadin possesses potent antioxidant property, it can prevent lipid peroxidation induced by FeSO4 and t-butylhydroperoxide (t-BHP) in a dose dependent manner.

  • VK-II-36

    VK-II-36, a carvedilol analog, suppresses sarcoplasmic reticulum (SR) Ca(2+) release but does not block the β-receptor.